NCT06770088View on ClinicalTrials.gov

Vunakizumab in Adults with Spondyloarthritis

PHASE4Not yet recruitingINTERVENTIONAL

Enrollment

880

Participants

Timeline

Start Date

January 10, 2025

Primary Completion Date

January 10, 2026

Study Completion Date

December 31, 2027

Conditions

Spondyloarthritis (SpA)

Interventions

DRUG

vnacicizumab

Vunakizumab 120 mg subcutaneous injection at baseline and week2, week4, then every other 4 weeks.

All Listed Sponsors

lead

Sun Yat-sen University

OTHER